AGM
LRMR icon

Alpine Global Management’s Larimar Therapeutics LRMR Stock Holding History

Alpine Global Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,090
Closed -$109K – 315
2024
Q2 		$109K Buy
+15,090
New +$116K 0.02% 399

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Alpine Global Management's LRMR Position: Q3 2024 in Review

Alpine Global Management sold out of Larimar Therapeutics (LRMR) in Q3 2024, closing a stake of 15,090 shares — an estimated $109K sold.

Alpine Global Management first reported a position in LRMR in Q2 2024 and held it in 1 quarter. The position peaked at $109K in Q2 2024. 123 funds tracked by Wall St. Rank hold LRMR as of Q3 2024.

  • Alpine Global Management reported no remaining Larimar Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 15,090 Larimar Therapeutics shares in Q3 2024, an estimated $109K.
  • Alpine Global Management first reported a position in Larimar Therapeutics in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's Larimar Therapeutics position peaked at $109K in Q2 2024.
  • 123 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.